YourVoice.Now Summary
Corporate BenefitsTransparency & AccountabilityCreates a U.S. drug trade negotiator and yearly public reports on wealthy countries' medicine rules — nothing changes at the pharmacy.
Corporate Benefits
The bill would add a Chief Pharmaceutical Trade Negotiator to the U.S. Trade Representative's office, at the rank of ambassador. The President would name the person and the Senate would vote on them. The job is to press foreign governments to open their markets to American medicines. The bill says this negotiator speaks for drug buyers as well as drug makers.
The response plan may propose an investigation under Section 301 of the Trade Act of 1974. That is the law the United States uses to put tariffs or other penalties on a country's goods. Today the Trade Representative can look into foreign drug rules but is not required to. The bill makes the looking yearly and the written plan mandatory, while leaving any penalty up to the agency.
Transparency & Accountability
Every year the Trade Representative would review how each wealthy foreign country treats American medicines. The report would name whether a country's rules are unfair, closed to U.S. products, or break a trade deal. It goes to the House Ways and Means and Senate Finance committees and onto a public U.S. Trade Representative website. Which countries are covered comes from the World Bank's high-income list, updated each year.
Once the Trade Representative decides a country's drug rules meet any of the bill's unfairness tests, a written response plan must go to those two committees within 30 days. The clock starts at that decision, not at the yearly report. Unlike the report, the plan does not have to be made public.
More about this bill
Drug prices in the United States would not change under this bill. It looks outward, at how wealthy foreign countries treat American medicines. Each year the U.S. Trade Representative would have to review every one of those countries. The review would go to two committees in Congress and onto a public website. The World Bank decides which countries count as wealthy. Its high-income group holds more than 80 countries today. That list is redrawn each year. The bill would also create a new post, a Chief Pharmaceutical Trade Negotiator. The President would name the person, and the Senate would vote. Say the Trade Representative decides a country's drug rules are unfair. A plan to respond would then have to reach Congress within 30 days. That plan may propose a case under Section 301 of the Trade Act. Section 301 is the law behind U.S. tariffs. But the bill orders no tariff of its own.
Congressional Summary
Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States. The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.
Details
- Congress
- 119th
- Chamber
- Senate
- Status
- summarized
- Action
- Introduced in Senate
- Action Date
- 2026-08-05
- Date Added
- 2026-09-16
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.